Abstracts tagged "Cardiovascular disease"

Abstract Number: 401 • 2013 ACR/ARHP Annual Meeting
Chest Pain Is Not Associated With Coronary Atherosclerosis In Patients With Rheumatoid Arthritis and Ankylosing Spondylitis
Silvia Rollefstad¹, Eirik Ikdahl², Inge C. Olsen³, Jonny Hisdal⁴, Tore K. Kvien^5,6, Anne S. Eirheim², Terje R. Pedersen⁶ and Anne G. Semb², ¹Rhuematology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Section of Vascular Investigations, Uslo University Hospital-Aker, Oslo, Norway, ⁵Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Faculty of Medicine, University of Oslo, Oslo, Norway
Background/Purpose: During cardiovascular (CV) risk stratification in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS), it can be difficult to distinguish between chest pain…
Abstract Number: 287 • 2013 ACR/ARHP Annual Meeting
Long-Term Evaluation Of Cardiac Function In Juvenile Idiopathic Arthritis Under Anti-Tumor Necrosis Factor Therapy
Alessandro C. Lianza¹, Nadia E. Aikawa², Julio C. B. Moraes³, Gabriela N. Leal⁴, Samira S. Morhy⁵, Eloisa Bonfa⁶ and Clovis A. Silva⁷, ¹Radiology, University of São Paulo, Sao Paulo, Brazil, ²Rheumatology, University of São Paulo, Sao Paulo, Brazil, ³Reumatologia, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Radiology Division, University of São Paulo, Sao Paulo, Brazil, ⁵Radiology Unit, University of São Paulo, Sao Paulo, Brazil, ⁶Rheumatology Division, University of São Paulo, Sao Paulo, Brazil, ⁷Children's Institute, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil
Background/Purpose: Subclinical cardiac involvement was previously described in juvenile idiopathic arthritis (JIA) patients, however there is no data regarding echocardiography and cardiac biomarkers evaluations in…
Abstract Number: 1702 • 2012 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Blocking Agents Inhibit the Progression of Preclinical Atherosclerosis in Patients with Ankylosing Spondylitis
Alper M. van Sijl¹, Izhar C. van Eijk², Mike J.L. Peters³, Erik H. Serne³, Yvo M. Smulders⁴ and Mike T. Nurmohamed¹, ¹Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ³Internal medicine, VU University Medical Center, Amsterdam, Netherlands, ⁴Internal Medicine, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Ankylosing spondylitis (AS) is associated with an increased cardiovascular (CV) risk that might be due to the chronic underlying inflammatory process. It is still…
Abstract Number: 1245 • 2012 ACR/ARHP Annual Meeting
Age-Specific Association Between Disease-Related Measures and Incident Cardiovascular Events and All-Cause Mortality in Early Rheumatoid Arthritis
Sofia Ajeganova¹, Maria LE Andersson², Johan Frostegård³ and Ingiäld Hafström¹, ¹Karolinska Institutet, Unit of Rheumatology, Department of Medicine Huddinge, Stockholm, Sweden, ²R&D Center, Spenshult Hospital, Oskarström, Sweden, ³Karolinska Institutet, Section of Immunology and chronic disease, Institute of Environmental Medicine, Stockholm, Sweden
Background/Purpose: Increased risk of cardiovascular disease (CVD) and premature mortality in rheumatoid arthritis (RA) has been established, but the impact of inflammatory and disease related…
Abstract Number: 350 • 2012 ACR/ARHP Annual Meeting
Reduction of Inflammation with Abatacept and Tocilizumab Results in Lower N-Terminal Pro Brain Natriuretic Peptide Levels in Patients with Rheumatoid Arthritis: Results From Prospective Cohort Studies
Inge A.M. van den Oever and Mike T. Nurmohamed, Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) patients are at increased risk of heart failure (HF). The chronic inflammatory state in RA is associated with increased levels of…
Abstract Number: 1682 • 2012 ACR/ARHP Annual Meeting
Sustained Clinical Remission (Disease Activity Score 28 <2.6) Protects for Cardiovascular Disease in Rheumatoid Arthritis Patients
Elke.E.A. Arts¹, Jaap Fransen², Alfons A. den Broeder³, Calin Popa¹ and Piet L.C.M. van Riel¹, ¹Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Chronic inflammation appears to be an independent risk factor for CVD in rheumatoid arthritis (RA), but there is no clear difference in CVD risk…
Abstract Number: 1253 • 2012 ACR/ARHP Annual Meeting
Identifying Vulnerable Plaque in Rheumatoid Arthritis: A Pilot Study Using Novel Microbubble-Contrast Enhanced Carotid Ultrasonography
Kimberly P. Liang¹, Douglas P. Landsittel², Suresh R. Mulukutla³, Steven E. Reis⁴, Marc C. Levesque¹, Flordeliza S. Villanueva³, Hunter C. Champion⁵ and Larry W. Moreland¹, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Medicine, Biostatistics and Clinical and Translational Science, University of Pittsburgh, Center for Health Care Research Data Center, Pittsburgh, PA, ³Division of Cardiology, University of Pittsburgh, Pittsburgh, PA, ⁴Division of Cardiology and Department of Clinical and Translational Science, University of Pittsburgh, Pittsburgh, PA, ⁵Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Rheumatoid arthritis (RA) is independently associated with a higher risk of cardiovascular disease (CVD). Markers of systemic inflammation, as seen in RA, are associated…
Abstract Number: 210 • 2012 ACR/ARHP Annual Meeting
An Analysis of Metabolic Syndrome in Adult Dermatomyositis with a Focus On Cardiovascular Disease
Mariana T. Moraes¹, Fernando H.C. Souza², Thiago B. M. Barros¹ and Samuel K. Shinjo¹, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Metabolic syndrome (MetS) is a cluster of metabolic abnormalities associated with increased cardiovascular risk. MetS has been systematically evaluated in all systemic autoimmune rheumatic…
Abstract Number: 1686 • 2012 ACR/ARHP Annual Meeting
Vertebral Fracture Assessment-Detected Abdominal Aortic Calcification Enhances Cardiovascular Disease Risk Stratification of Rheumatoid Arthritis Patients
Ausaf Mohammad¹, Derek Lohan², Diane Bergin², Sarah Mooney², John Newell³, Martin O'Donnell⁴, Robert J. Coughlan¹ and John J. Carey¹, ¹Rheumatology, Galway University Hospitals, Galway, Ireland, ²Radiology, Galway University Hospitals, Galway, Ireland, ³Clinical Research Facility, National University of Ireland, Galway, Ireland, ⁴Clinical Research Facility, Galway University Hospitals, Galway, Ireland
Vertebral Fracture Assessment-detected Abdominal Aortic Calcification Enhances Cardiovascular Disease Risk Stratification of Rheumatoid Arthritis Patients Background/Purpose: Osteoporosis and cardiovascular disease (CVD) are major comorbidities and CVD…
Abstract Number: 1255 • 2012 ACR/ARHP Annual Meeting
Vascular Calcification On Hand and Feet X-Rays, VFA Imaging of the Spine, and Cardiovascular Disease in Rheumatoid Arthritis
Ausaf Mohammad¹, Collette English², Derek Lohan², Diane Bergin², Sarah Mooney², John Newell³, Martin O'Donnell⁴, Robert J. Coughlan¹ and John J. Carey¹, ¹Rheumatology, Galway University Hospitals, Galway, Ireland, ²Radiology, Galway University Hospitals, Galway, Ireland, ³Clinical Research Facility, National University of Ireland, Galway, Ireland, ⁴Clinical Research Facility, Galway University Hospitals, Galway, Ireland
Vascular Calcification on Hand and Feet X-rays, VFA imaging of the spine, and Cardiovascular Disease in Rheumatoid ArthritisBackground/Purpose: Patients with rheumatoid arthritis (RA) are at…
Abstract Number: 161 • 2012 ACR/ARHP Annual Meeting
Increased Serum Uric Acid: Consequence or Cause of Increased Cardiovascular Risk
Inger L. Meek¹, Harald E. Vonkeman² and Mart A.F.J. van de Laar³, ¹Rheumatology & Clinical Immunology, Rheumatology Center Twente, Medisch Spectrum Twente & Twente University, Enschede, Netherlands, ²Rheumatology Center Twente, Medisch Spectrum Twente & Twente University, Enschede, Netherlands, ³Rheumatology, Medisch Spectrum Twente & University of Twente, Enschede, Netherlands
Background/Purpose: Reports on cardiovascular (CV) disease in hyperuricemia and gout show conflicting results. Some studies show hyperuricemia to be an independent risk factor for CV…
Abstract Number: 1668 • 2012 ACR/ARHP Annual Meeting
Improving the Accuracy of Cardiovascular Risk Prediction in Rheumatoid Arthritis with a New Predictive Model Using the 10-Year Prospective Carre-Study
Alper M. van Sijl¹, Inge A.M. van den Oever¹, Mike J.L. Peters², Vokko P. van Halm³, Alexandre E. Voskuyl⁴, Yvo M. Smulders⁵ and Mike T. Nurmohamed¹, ¹Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²Internal medicine, VU University Medical Center, Amsterdam, Netherlands, ³Cardiology, Academic Medical Centre, Amsterdam, Netherlands, ⁴Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁵Internal Medicine, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory joint disease which is associated with an increased cardiovascular (CV) risk. Traditional CV risk factors do not…
Abstract Number: 1198 • 2012 ACR/ARHP Annual Meeting
Cardiovascular Risk Factors and Events Are More Frequent Prior to the Onset of Rheumatoid Arthritis Than in the General Population
Helen Pahau Sr.¹, Vibeke Videm², Sanjoy Paul³ and Ranjeny Thomas⁴, ¹Diamantina Institute, University of Queensland Diamantina Institute, Brisbane, Australia, ²Department of Laboratory Medicine, Children's and Women's Health, Norwegian University of Science and Technology, and Department of Immunology and Transfusion Medicine, Trondheim University Hospital,, Trondheim, Norway, ³University of Queensland School of Population Health, Brisbane, Australia, ⁴University of Queensland Diamantina Institute, Brisbane, Australia
Background/Purpose: Patients with the inflammatory autoimmune disease Rheumatoid Arthritis (RA) have a higher mortality and morbidity than the general population, predominantly related to cardiovascular disease…
Abstract Number: 165 • 2012 ACR/ARHP Annual Meeting
Colchicine Is Associated with a Decreased Rate of Myocardial Infarction in Gout Patients: Interim Results From a Retrospective Cohort Study
Daria B. Crittenden¹, Cilian J. White¹, Michael DeBerardine¹, Grace Kim², Binita Shah³, Jessica C. Kimmel¹, Rima D. Patel¹, Steven P. Sedlis³, Jeffrey D. Greenberg⁴, Craig T. Tenner⁵, Bruce N. Cronstein¹ and Michael H. Pillinger¹, ¹Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY, ²NYU School of Medicine, Division of Rheumatology, New York, NY, ³NYU School of Medicine, Division of Cardiology, New York, NY, ⁴Division of Rheumatology, Department of Medicine, NYU Hospital for Joint Diseases, New York, NY, ⁵Internal Medicine, NYU School of Medicine, Department of Internal Medicine, New York, NY
Background/Purpose: Atherosclerosis is an inflammatory process, but to date no anti-inflammatory agent has definitively been shown to alter cardiovascular (CV) risk. Colchicine is an anti-inflammatory…
Abstract Number: 2568 • 2012 ACR/ARHP Annual Meeting
The Risk of Pulmonary Embolism and Deep Vein Thrombosis in Giant Cell Arteritis: A Population-Based Cohort Study
J. Antonio Avina-Zubieta¹, Diane Lacaille², Eric C. Sayre³, Jacek A. Kopec³ and Hyon Choi⁴, ¹Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada, ²Rheumatology, Arthritis Research Centre of Canada/University of British Columbia, Richmond, BC, Canada, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Arthritis Research Centre of Canada/University of British Columbia, Boston, MA
Background/Purpose: A recent hospital-based study has suggested an 8 fold increased risk of pulmonary embolism (PE) in individuals with polymyalgia rheumatica in the year following…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].